Global prediabetes market is anticipated to grow at a CAGR of 7.2% during the forecast period (2024-2031). A major factor supporting the growth of the market is the increasing product expansion and new drugs in the market. For instance, in January 2024, Novo Nordisk announced the launch of its Wegovy, a GLP-1 analog in the UK. This drug can be prescribed to people with prediabetes and for weight loss purposes. Similarly, some of the other product launches include-
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/prediabetes-market
- In November 2023, Valbiotis, a commercially oriented R&D company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases (CVDs), announced the successful completion of the mode of action clinical study on TOTUM•63, against prediabetes and the early stages of Type 2 diabetes.
- In April 2023, PharmaLinea launched Prediabetiq capsules, a clinically supported private-label food supplement that aims to reduce post-meal blood glucose levels and improve insulin efficacy and sensitivity. According to PharmaLinea, the product’s key active ingredient Qgluco, reduced mean blood glucose by 45% 60 minutes after a meal when compared to a placebo. The company expects the market for diabetes and prediabetes supplements to grow due to increasing diabetes rates, consumer awareness of glucose control, and increased use of continuous blood glucose monitors.
- In April 2023, Nestlé USA launched a new line of ready meals for people managing their blood sugar levels, building on similar launches in Malaysia and China -and products that help control blood sugar levels are in trend. It launched under its Lean Cuisine brand, the Balance Bowls range which contains four stock-keeping units (SKUs): Tex-Mex Rice and Black Beans; Lemon Garlic Shrimp Stir-Fry; Roasted Eggplant Parmesan Pasta; and Creamy Pasta Primavera.
Global Prediabetes Market Report Segment
By Drug Class
- Diguanide
- Thiazolidinediones (TZDS)
- Glucagon-like Peptide-1 Agonists (GLP-1)
- SGLT2 Inhibitors
- DPP-4 Inhibitors
- Others (Glucagon-like peptide 1 (GLP-1), Sulfonylureas)
By Age Group
- Children (12 to 18 Years)
- Adult (18 to 50 Years)
- Elderly (Above 50 Years)
A full report of Prediabetes Market is available at: https://www.omrglobal.com/industry-reports/prediabetes-market
Global Prediabetes Market Report Segment by Region
North America
- United States
- Canada
Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
- Middle East & Africa
- Latin America
Company Profiles
- Aphaia Pharma
- AstraZeneca
- Boehringer Ingelheim International GmbH
- Boston Pharmaceuticals
- Bristol-Myers Squibb
- Caelus Health
- Dexcom, Inc.
- DIABETOMICS, Inc.
- Eli Lilly and Company
- Johnson & Johnson Services, Inc.
- Medtronic Private Limited
- Merck KGaA
Reasons to Buying From us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
Visit more report at
https://www.linkedin.com/pulse/scaffold-technology-market-size-trends-latest-arti-vishwakarma-mlsof/
